Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICAA Trial of methylphenidate in children with ADHD and autism
ACTRN12623001147673Phase 4Not yet recruiting
- Sponsor
- Professor Katrina Williams
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate and Placebo-COD Research Private Ltd in attention deficit hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD), sponsored by Professor Katrina Williams. Primary endpoints: Teacher-rated ADHD traits at individual level and Parent-rated ADHD traits at individual level. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
methylphenidatePlacebo-COD Research Private Ltd
03
Conditions
attention deficit hyperactivity disorder (ADHD)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12623001147673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001147673.